History
3.0 Leap of the GC Genome
Advancing Overseas Expansion and Diversification Toward Becoming a Global Genomics Company
2024
– Launched “M-screen,” a genomic testing service for analyzing miscarriage causes.
May
– Presented at the American Society of Clinical Oncology (ASCO 2024) on “Non-invasive colorectal cancer detection using a multimodal deep learning ensemble classifier.”
April
– Co-presented six liquid biopsy research findings at the American Association for Cancer Research (AACR 2024), including “Evaluation of analytical variables in cancer detection analysis using cell-free DNA fragments.”
2023
– Exported genome health check genetic testing technology to Thailand.
October
– Presented at the European Society for Medical Oncology (ESMO 2023) on developing a deep learning algorithm for lung cancer diagnosis using cell-free DNA methylation and fragment size profiling.
September
– Launched AI-CANCERCH, an AI-based multi-cancer early screening test.
July
– Released “GeneSketch,” a personalized health management genetic testing service.
April
– Published a research paper on early cancer detection algorithms in Nature Communications.
March
– Signed a licensing agreement with Genece Health (USA) for liquid biopsy core technology.
January
– Launched vaginal microbiome testing service “GreenBiome Lady.”
2022
December
– Expanded the GC Genome branch in Yongin.
October
– Registered a patent for detecting chromosomal abnormalities using inter-fragment distance information of nucleic acids.
– Launched Guardant Reveal™ for predicting the recurrence risk of colorectal cancer via liquid biopsy in Korea.
September
– Introduced a hair loss risk screening test.
– Presented at ESMO 2022 on “Deep learning-based multimodal ensemble algorithms for multi-cancer detection and classification using cell-free DNA WGS.”
June
– Registered a patent for chromosomal abnormality detection methods based on whole-genome sequencing.
April
– Designated as a GCLP-compliant clinical trial sample analysis institution by the Ministry of Food and Drug Safety (MFDS).
– Presented AI-based liquid biopsy technology at AACR 2022.
– Renamed the company to GC Genome.
– Selected by KHIDI as a national project institute for the commercialization of a liquid biopsy biomarker-based lung cancer early detection test.
March
– Received the first domestic approval for a new medical technology for GreenPlan HRD.
2.0. Growth of the GC genome
Building a Product Portfolio and Securing Growth Drivers
2021
November
– Selected as one of the “Top 10 Lighthouse Companies” at the Ministry of Trade, Industry, and Energy’s Global Innovation Conference for Mid-sized Companies.
July
– Launched “Genome Health,” a genetic test for cancer and general disease susceptibility.
June
– Presented at the Korean Cancer Association (2021) on “AI-based Early Cancer Detection and Minimal Residual Disease Detection using Cell-Free DNA-WGS.”
May
– Introduced Telorisk, a test for measuring aging speed
– Launched the “GreenBiome Obesity” test to analyze gut microbiota linked to obesity.
April
– Expanded testing facilities and established a data center.
– Launched the “GreenPlan HRD” test for homologous recombination deficiency (HRD).
February
– Selected for KOTRA’s Global Support Program for Mid-sized Companies.
2020
November
– Officially launched the “GC Genome” Naver Blog.
October
– Chosen as a national project partner by the Korea Health Industry Development Institute (KHIDI) to establish a genomic data integration system for AI-based liver cancer early detection and minimal residual disease monitoring.
September
– Selected as a national project partner by the Science and Technology Job Foundation for developing an AI-integrated RNA pattern-based HRD test to guide ovarian cancer treatment.
July
– Undertook a national project supported by the National Research Foundation of Korea (NRF) to develop tests predicting radiotherapy outcomes using AI-trained liquid biopsy genomic data.
April
– Released “Risk Screen Plus,” a genetic test for health screening focused on genetic vulnerability to diseases.
March
– Launched the “GreenBiome Perio&Denti” test for oral microbiota analysis.
February
– Introduced “DGS,” a diagnostic whole-genome sequencing test.
January
– Registered a patent for a genetic marker predicting blood statin drug concentrations.
2019
October
– Launched the “GreenBiome Gut” test for gut microbiota analysis.
September
– Registered a patent for core technology in liquid biopsy.
July
– Launched the Guardant360 liquid biopsy test in Korea.
June
– Selected by the Korea Evaluation Institute of Industrial Technology (KEIT) as a national project partner to develop an AI-integrated diagnostic device combining genomic analysis data for predicting treatment responses in hepatocellular carcinoma.
May
– Undertook a national project by KEIT to commercialize next-generation sequencing (NGS)-based liquid biopsy technology for guiding breast cancer treatment.
April
– Chosen by the Korea Health Industry Development Institute (KHIDI) for a national project to develop and validate genomic analysis-based liquid biopsy technology for predicting treatment responses in pancreatic cancer.
2018
August
– Relocated the cell center.
April
– Released “Risk Screen,” a genetic test identifying vulnerabilities to health screening conditions.
– Launched “Genome Screen,” an NGS test for detecting broad genetic mutations associated with hereditary diseases.
2017
November
– Designated as the lead organization for the Korea-Czech International Joint Technology Development Project by the Ministry of Trade, Industry, and Energy (MOTIE).
October
– Selected as a participant in MOTIE’s core technology development project for the bioindustry.
September
– Registered a patent for SNP markers related to hemophilia treatment.
July
– Released “Gene Doctor,” a wellness health screening genetic test.
April
– Received NGS clinical laboratory certification from the Ministry of Food and Drug Safety (MFDS).
February
– Earned accreditation from the College of American Pathologists (CAP).
1.0. Birth of the GC Genome
Establishing Foundational Technologies
2016
December
– Obtained a patent for the G-NIPT and proprietary algorithm.
September
– Launched the newborn genomic screening test “i-screen.”
March
– Selected as a pilot institution for the Ministry of Food and Drug Safety (MFDS) NGS clinical laboratory certification program.
2015
November
– Launched the “Drug Compatibility DNA” test.
August
– Designated as the lead organization for the Post-Genome Multi-Ministerial Genomic Project.
July
– Received an A grade for accuracy in genetic testing from the Korean Genome Testing Evaluation Institute.
April
– Launched the non-invasive prenatal chromosome abnormality screening test “G-NIPT.”
2014
April
– Launched new genomic analysis test items, including the diagnostic exome sequencing test (DES), Type 1 dystonia, and Women’s Cancer Protection tests.
2013
December
– Established a corporate research institute.
August
– Incorporated as GC Genome Co., Ltd.
– Registered as a genetic testing institution.
